Contents
Download PDF
pdf Download XML
221 Views
144 Downloads
Share this article
Research Article | Volume 13 Issue:4 (, 2023) | Pages 1664 - 1670
Comparative Study of Safety, Efficacy of Metformin versus Pioglitazone on HOMA-IR, and HbA1c in prediabetes patient
 ,
1
Research Scholar, Department of Pharmacology, Index Medical College Hospital and Research Center, Malwanchal University
2
Professor, Department of Pharmacology, Index Medical College Hospital and Research Center, Malwanchal University
Under a Creative Commons license
Open Access
Received
Nov. 1, 2023
Revised
Nov. 15, 2023
Accepted
Nov. 29, 2023
Published
Dec. 11, 2023
Abstract

Background:  Prediabetes defined as blood glucose levels above the normal but below thresholds for diagnosis of diabetes, is a risk state that defines a high chance of developing diabetes. Metformin, a biguanide class of oral hypoglycaemic drug, is the first line drug for the management of type 2 DM. Pioglitazone, insulin-sensitizing Thiazolidinedione’s (TZDs), is commonly prescribed for the treatment of type 2 diabetes. TZDs are known to activate a peroxisome proliferator-activated Receptor- γ (PPAR- γ) which are ligand-activated transcription factors which belongs to the nuclear receptor superfamily. HOMA-IR is a simple and predominantly helpful laboratory tool in the evaluation of insulin resistance in prevalence studies. Material and Methods: Present study is Comparative, Prospective, randomized, Open-label, Single Center, Parallel group study conducted in Department of pharmacology at Index Medical college. Study was conducted in prediabetes patients for assessment of effects of Metformin and Pioglitazone. All patients were evaluated at baseline, 3 months for clinical and physical examination and laboratory investigation. Results: The mean difference of Fasting Blood Glucose level in Pioglitazone at baseline and after 3 months was found to be 23.8 mg/dl. The mean difference of Fasting Blood Glucose level in Metformin at baseline and after 3 months was found to be 12 mg/dl. Moreover, mean difference of Post-lunch Blood Glucose level in Pioglitazone at baseline and after 3 months was found to be 31.8 mg/dl. The mean difference of Post-lunch Blood Glucose level in Metformin at baseline and after 3 months was found to be 24 mg/dl. Conclusion: After 3 months’ treatment with Metformin and Pioglitazone, showed statically significant reduction in Blood glucose level, HOMA-IR, Serum insulin, HbA1c, Lipid Profile values. Whereas, after 3 months of treatment with Metformin and Pioglitazone caused reduction in FBG, HOMA-IR, Serum insulin, HbA1c, Lipid Profile values statistically significant decreased compare with Metformin and Pioglitazone. On the hand, Metformin reduced PPBG level, statistically highly significant compared with Pioglitazone group.

 

Keywords
Recommended Articles
Research Article
Study Of Automated Red Cell Exchange in The Management of Sickle Cell Disease in A Tertiary Care Hospital of Indore District
...
Published: 08/02/2025
Download PDF
Research Article
Correlation of Platelet Indices with Thrombocytosis: A Clinicopathological Study in a Tertiary Care Hospital
Published: 30/06/2023
Download PDF
Research Article
Fixation of pertrochanteric fracture with proximal femoral nail in adults
Published: 20/09/2018
Download PDF
Research Article
A Study on Complication During Therapeutic Plasma Exchange in A Tertiary Care Hospital of Central India
...
Published: 08/02/2025
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.